NIH clinical trial testing antiviral remdesivir plus anti-inflammatory baricitinib for COVID-19 begins.
A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019… read more.